Literature DB >> 19730439

Non-dipping pattern in ambulatory blood pressure monitoring is associated with metabolic abnormalities in a random sample of middle-aged subjects.

Olavi Ukkola1, Riitta-Liisa Vasunta, Y Antero Kesäniemi.   

Abstract

A reduction in the blood pressure decline at night (<10% from daytime systolic blood pressure (SBP)) during 24-h ambulatory blood pressure monitoring (ABPM) ('non-dipping pattern') is associated with cardiovascular morbidity. Our aim was to evaluate whether ABPM characteristics are associated with metabolic abnormalities in subjects without known hypertension or type 2 diabetes mellitus (T2DM). This is a cross-sectional population-based study on middle-aged subjects (n=462). Two distinct definitions of metabolic syndrome (MetS) were used: National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) and International Diabetes Federation (IDF) criteria. Results suggested that subjects characterized by non-dipping in 24 h ABPM were more obese (P=0.014). After adjustment for body mass index, age and sex, non-dippers had higher very-low-density lipoprotein (VLDL)-cholesterol (P=0.003), total (P=0.029)-and VLDL-triglycerides (P=0.026) and oral glucose tolerance test 2 h blood glucose (P=0.027) compared with dippers. Non-dipping status was more common among subjects with MetS (P< or =0.01), impaired glucose tolerance (IGT) (P<0.05) and in those with the combination of IGT-T2DM (P< or =0.01) than among those without these abnormalities. ABPM non-dipping status was an independent predictor of IGT in multivariate models (P<0.05). With respect to MetS components, high triglycerides (P< or =0.005) and low high density lipoprotein-cholesterol (P<0.05) were associated with a non-dipping pattern. The percentage decline in blood pressure from day to night decreased with the number of metabolic abnormalities (P=0.012). In conclusion, ABPM non-dipping status is an independent predictor of glucose intolerance. It is also associated with several other metabolic abnormalities. Whether non-dipping pattern is causally related to these metabolic aberrations remains to be explored in a future prospective follow-up of this cohort.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19730439     DOI: 10.1038/hr.2009.137

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  7 in total

Review 1.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

Review 2.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.

Authors:  Asadur Rahman; Hirofumi Hitomi; Akira Nishiyama
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

Review 3.  Complex physiology and clinical implications of time-restricted eating.

Authors:  Max C Petersen; Molly R Gallop; Stephany Flores Ramos; Amir Zarrinpar; Josiane L Broussard; Maria Chondronikola; Amandine Chaix; Samuel Klein
Journal:  Physiol Rev       Date:  2022-07-14       Impact factor: 46.500

4.  Associations between nocturnal blood pressure dipping and the metabolic syndrome in high- vs. low-acculturated Mexican American women.

Authors:  Smriti Shivpuri; Matthew A Allison; Caroline A Macera; Suzanne Lindsay; Linda C Gallo
Journal:  Am J Hypertens       Date:  2013-05-03       Impact factor: 2.689

5.  Ambulatory blood pressure monitoring in diabetes and obesity-a review.

Authors:  Kazuo Eguchi
Journal:  Int J Hypertens       Date:  2011-03-28       Impact factor: 2.420

6.  Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study.

Authors:  Florence Gunawan; Hui Yi Ng; Christopher Gilfillan; Mahesan Anpalahan
Journal:  Curr Hypertens Rev       Date:  2019

7.  Echocardiographic indices of left ventricular hypertrophy and diastolic function in hypertensive patients with preserved LVEF classified as dippers and non-dippers.

Authors:  Monika Możdżan; Karina Wierzbowska-Drabik; Małgorzata Kurpesa; Ewa Trzos; Tomasz Rechciński; Marlena Broncel; Jarosław D Kasprzak
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.